Adenocarcinoma of the Pancreas Recruiting Phase 2 Trials for Gemcitabine (DB00441)

Also known as: Pancreatic adenocarcinoma / Adenocarcinoma Pancreas / Pancreas, Adenocarcinoma / Pancreas Adenocarcinoma / Adenocarcinoma of Pancreas / Adenocarcinoma, Pancreas

IndicationStatusPhase
DBCOND0029532 (Adenocarcinoma of the Pancreas)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02564146First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and GemcitabineTreatment
NCT03492671Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic CancerTreatment
NCT02562716S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by SurgeryTreatment
NCT02806687Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic CancerTreatment
NCT03138720Pre-operative Treatment for Patients With Untreated Pancreatic CancerTreatment
NCT02427841Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by SurgeryTreatment
NCT03415854Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)Treatment
NCT01897454Combination Chemotherapy, Gemcitabine Hydrochloride, and Radiation Therapy Before Surgery in Treating Patients With Borderline Resectable Pancreatic CancerTreatment